优化了与阿尔茨海默病相关的APOE4突变的主要编辑
Antje K Rottner1, Anders Lundin1, Songyuan Li1
1Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden.
Stem cell reports
|December 6, 2024
概括
研究人员优化了主要编辑 (PE) 以精确修改与阿尔茨海默病相关的APOE4基因. 使用喉毒素共同选择的新丰富策略增强了基因组工程,用于创建APOE4疾病模型.
科学领域:
- 遗传学 遗传学 是一个
- 神经科学是一个神经科学.
- 生物技术是生物技术.
背景情况:
- APOE4异型是阿尔茨海默病 (AD) 的重要遗传风险因素.
- 现有的基因编辑方法在安全有效地准APOE4基因方面面临挑战.
- 主编辑 (PE) 提供了精确的基因修饰,没有捐赠者DNA,但其应用到APOE4需要优化.
研究的目的:
- 选和优化主要编辑参数,以引入APOE4变种.
- 为了产生与阿尔茨海默病相关的人类诱导多能干细胞 (hiPSC) 模型.
- 为精确的基因组编辑开发一个高效的丰富策略.
主要方法:
- 选主要编辑指导RNA (pegRNA) 参数和PE系统.
- 应用优化的PE策略来生成APOE4特定的hiPSC模型.
- 开发用于PE丰富的喉毒素共同选择方法.
主要成果:
- 为APOE4编辑实现了PE系统和pegRNA参数的优化.
- 引入APOE4校正的单核酸差异被发现可以抑制PE活性.
- 一个可靠的PE丰富策略使用喉毒素共同选择已成功开发和验证.
结论:
- 该研究提供了一个优化和可重复的管道,用于使用主要编辑生成APOE4疾病模型.
- 概述了新的策略,以加速基因组编辑用于细胞疾病模型生成.
- 这项工作推动了基因变异的精确工程,用于研究像阿尔茨海默氏症这样的复杂疾病.
相关概念视频
RNA Editing
8.9K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
8.9K
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163


